How nanotechnology can enhance docetaxel therapy

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 2927-2941

  Zhang, Li ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cancer therapy; Docetaxel; Nanoformulations; Nanotechnology; Target delivery systems

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; ARGINYLGLYCYLASPARTIC ACID; CHITOSAN; CYCLODEXTRIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; FOLIC ACID; FULLERENE; HYALURONIC ACID; LIGAND; LIPID; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NANOCARRIER; NANOPARTICLE; OCTREOTIDE; PACLITAXEL; PEPTIDE; POLYGLACTIN; POLYGLUTAMIC ACID; POLYMER; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; TRANSFERRIN; TRASTUZUMAB; UNINDEXED DRUG;

ALOPECIA; ASTHENIA; BREAST METASTASIS; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOXICITY; FEBRILE NEUTROPENIA; FLUID RETENTION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LACRIMAL DUCT OCCLUSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MYALGIA; NAIL DISEASE; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PROSTATE CANCER; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR;

CANCER THERAPY; DOCETAXEL; NANOFORMULATIONS; NANOTECHNOLOGY; TARGET DELIVERY SYSTEMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; MICE; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TAXOIDS;

EID: 84881307918     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S46921     Document Type: Review

References (135)

1. Denis JN, Greene AE, Guenard D, Gueritte-Voegelein F, Mangatal L, Potier P. Highly efficient, practical approach to natural taxol. J Am Chem Soc. 1988;110(17):5917-5919.
2. Tan Q, Liu X, Fu X, Li Q, Dou J, Zhai G. Current development in nanoformulations of docetaxel. Expert Opin Drug Deliv. 2012;9(8):975-990.
3. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229-239.
4. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogs and their antimitotic activity. J Med Chem. 1991;34(3):992-998.
5. Zhao P, Astruc D. Docetaxel nanotechnology in anticancer therapy. Chem Med Chem. 2012;7(6):952-972.
6. Engels FK, Mathot RAA, Verweij J. Alternative drug formulations of docetaxel: a review. Anti-Cancer Drug. 2007;18(2):95-103.
7. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere®): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol. 1994;5(6):533-537.
8. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995;13(12):2886-2894.
9. Baker J, Ajani J, Scotté F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs. 2009;13(1):49-59.
10. Eckhoff L, Nielsen M, Moeller S, Knoop A. TAXTOX-a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009. Acta Oncol. 2011;50(7):1075-1082.
11. Roglio I, Bianchi R, Camozzi F, et al. Docetaxel-induced peripheral neuropathy: protective effects of dihydroprogesterone and progesterone in an experimental model. J Peripher Nerv Syst. 2009;14(1):36-44.
12. Verweij J, Catimel G, Sulkes A, et al. Phase II studies of docetaxel in the treatment of various solid tumours. Eur J Cancer. 1995;31(Suppl 4):S21-S24.
13. Yanasarn N, Sloat BR, Cui Z. Nanoparticles engineered from lecithinin-water emulsions as a potential delivery system for docetaxel. Int J Pharm. 2009;379(1):174-180.
14. Thiesen J, Krämer I. Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers. Pharm World Sci. 1999;21(3):137-141.
15. Hart M, Acott S. Physical and chemical stability of Taxotere® (docetaxel) one-vial (20 mg/mL) infusion solution following refrigerated storage. Ecancermedicalscience. 2010;4:202.
16. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin Cancer Res. 1999;5(1):83-94.
17. Liu Z, Wang Y, Zhang N. Micelle-like nanoassemblies based on polymer-drug conjugates as an emerging platform for drug delivery. Expert Opin Drug Deliv. 2012;9(7):805-822.
18. Mu CF, Balakrishnan P, Cui FD, et al. The effects of mixed MPEG- PLA/Pluronic® copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials. 2010;31(8):2371-2379.
19. Zheng Y, Huang L, Mei L. Docetaxel-loaded TPGS-b-(PLA-ran PGA) nanoparticles for cervix cancer treatment. Paper presented at: Bioinformatics and Biomedical Engineering, (iCBBE) 2011 5th International Conference on 2011.
20. Etrych T, Šírová M, Starovoytova L, Ríhová B, Ulbrich K. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. Mol Pharm. 2010;7(4):1015-1026.
21. Hwang HY, Kim IS, Kwon IC, Kim YH. Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release. 2008;128(1):23-31.
22. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 2001;47(1):113-131.
23. Elsabahy M, Perron M, Bertrand N, Yu G, Leroux J. Solubilization of docetaxel in poly (ethylene oxide)-block-poly (butylene/styrene oxide) micelles. Biomacromolecules. 2007;8(7):2250-2257.
24. Mikhail AS, Allen C. Poly (ethylene glycol)-b-poly (ε-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules. 2010;11(5):1273-1280.
25. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545-2561.
26. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.
27. Svenson S. Clinical translation of nanomedicines. Curr Opin Solid State Mater Sci. 2012;16(6):287-294.
28. Deng C, Jiang Y, Cheng R, Meng F, Zhong Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today. 2012;7(5):467-480.
29. Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine. 2012;8(Suppl 1):S31-S36.
30. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175-187.
31. Conte C, Ungaro F, Maglio G, et al. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn (II)-phthalocyanine inspired by combination therapy for cancer. J Control Release. 2013;167(1):40-52.
32. Khandare J, Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci. 2006;31(4):359-397.
33. Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev. 2009;61(13):1117-1120.
34. Ernsting MJ, Tang WL, MacCallum NW, Li SD. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials. 2012;33(5):1445-1454.
35. Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosanconjugated docetaxel after oral administration. J Control Release. 2009;140(2):79-85.
36. Buhleier E, Wehner W, Vögtle F. Cascade and nonskid-chain-like synthesis of molecular cavity topologies. Synthesis. 1978;2:155-158.
37. Dykes GM. Dendrimers: a review of their appeal and applications. J Chem Technol Biotechnol. 2001;76(9):903-918.
38. Nanjwade BK, Bechra HM, Derkar GK, Manvi F, Nanjwade VK. Dendrimers: emerging polymers for drug-delivery systems. Eur J Pharm Sci. 2009;38(3):185-196.
39. Tomalia DA. Starburstr̀ dendrimers - Nanoscopic supermolecules according to dendritic rules and principles. Macromol Symp.1996; 101(1):243-255.
40. Hawker CJ, Frechet JM. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J Am Chem Soc. 1990;112(21):7638-7647.
41. Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka LA. Drug delivery using multifunctional dendrimers and hyperbranched polymers. Expert Opin Drug Deliv. 2010;7(12):1387-1398.
42. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm. 2009;71(3):445-462.
43. Nayak AK, Dhara AK. Nanotechnology in drug delivery applications: a review. Arch Appl Sci Res. 2010;2(2):284-293.
44. Gajbhiye V, Jain NK. The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials. 2011;32(26):6213-6225.
45. 2k) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011;32(16):4058-4066.
46. Lee SW, Yun MH, Jeong SW, et al. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system. J Control Release. 2011;155(2):262-271.
47. Chaudhari KR, Kumar A, Khandelwal VKM, Mishra AK, Monkkonen J, Murthy RSR. Targeting efficiency and biodistribution of zoledronate conjugated docetaxel loaded pegylated PBCA nanoparticles for bone metastasis. Adv Funct Mater. 2012;22(19):4101-4114.
48. Cho H-J, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials. 2011;32(29):7181-7190.
49. Porter CJH, Pouton CW, Cuine JF, Charman WN. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Deliv Rev. 2008;60(6):673-691.
50. Beg S, Swain S, Rizwan M, Irfanuddin M, Shobha Malini D. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv. 2011;8(6):691-702.
51. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592-599.
52. Deeken JF, Slack R, Weiss GJ, et al. A phase I study of liposomalencapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmcol. 2013;71(3):627-633.
53. Mohanraj V, Chen Y. Nanoparticles-a review. Tropical Journal of Pharmaceutical Research. 2006;5(1):561-573.
54. Bamrungsap S, Zhao Z, Chen T, et al. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Nanomedicine. 2012;7(8):1253-1271.
55. Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2): 165-196.
56. Xu Z, Chen L, Gu W, et al. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials. 2009;30(2):226-232.
57. Das S, Ng WK, Tan RBH. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47(1):139-151.
58. Liu D, Liu F, Liu Z, Wang L, Zhang N. Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with antiVEGFR-2 antibody. Mol Pharm. 2011;8(6):2291-2301.
59. Wang L, Liu Z, Liu D, Liu C, Juan Z, Zhang N. Docetaxel-loadedlipid-based-nanosuspensions (DTX-LNS): preparation, pharmacokinetics, tissue distribution and antitumor activity. Int J Pharm. 2011;413(1):194-201.
60. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163(1):34-45.
61. Liu Y, Xie P, Zhang D, Zhang Q. A mini review of nanosuspensions development. J Drug Target. 2012;20(3):209-223.
62. Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int J Nanomedicine. 2012;7:3281-3294.
63. Muthu MS, Kulkarni SA, Xiong J, Feng S-S. Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm. 2011;421(2):332-340.
64. Muthu MS, Kulkarni SA, Raju A, Feng S-S. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials. 2012;33(12):3494-3501.
65. Venishetty VK, Samala R, Komuravelli R, Kuncha M, Sistla R, Diwan PV. β-hydroxybutyric acid grafted solid lipid nanoparticles: a novel strategy to improve drug delivery to brain. Nanomedicine. 2013;9(3):388-397.
66. Zhao X, ZhaoY, Geng L, et al. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier. J Chromatogr B. 2011;879(31):3721-3727.
67. Fang RH, Zhang L. Dispersion-based methods for the engineering and manufacture of polymeric nanoparticles for drug delivery applications. Journal of Nanoengineering and Nanomanufacturing. 2011;1(1):106-112.
68. Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloids Surf B Biointerfaces. 2011;85(2):214-220.
69. Tan S, Li X, Guo Y, Zhang Z. Lipid-enveloped hybrid nanoparticles for drug delivery. Nanoscale. 2013;5:860-872.
70. Zhang L, Zhang L. Lipid-polymer hybrid nanoparticles: synthesis, characterization and applications. Nano Life. 2010;1(01&02):163-173.
71. Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm. 2007;65(3): 300-308.
72. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 2010;31(2):330-338.
73. Bershteyn A, Chaparro J, Yau R, et al. Polymer-supported lipid shells, onions, and flowers. Soft matter. 2008;4(9):1787-1791.
74. Douroumis D. Mesoporous silica nanoparticles as drug delivery system. J Nanomed Nanotechnol. 2011;2:3.
75. Mamaeva V, Sahlgren C, Lindén M. Mesoporous silica nanoparticles in medicine-recent advances. Adv Drug Deliv Rev. 2012.
76. Slowing II, Vivero-Escoto JL, Wu CW, Lin VSY. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60(11):1278-1288.
77. He Q, Shi J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem. 2011;21(16): 5845-5855.
78. Sun JT, Hong CY, Pan CY. Fabrication of PDEAEMA-coated mesoporous silica nanoparticles and pH-responsive controlled release. J Phys Chem C. 2010;114(29):12481-12486.
79. Lebret V, Raehm L, Durand JO, et al. Folic acid-targeted mesoporous silica nanoparticles for two-photon fluorescence. J Biomed Nanotechnol. 2010;6(2):176-180.
80. Li L, Tang F, Liu H, et al. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. Acs Nano. 2010;4(11):6874-6882.
81. Chen Y, Chen H, Ma M, et al. Double mesoporous silica shelled spherical/ellipsoidal nanostructures: synthesis and hydrophilic/ hydrophobic anticancer drug delivery. J Mater Chem. 2011;21(14): 5290-5298.
82. Ghosh P, Han G, De M, Kim CK, Rotello VM. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev. 2008;60(11):1307-1315.
83. Khlebtsov N, Dykman L. Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2011;40(3):1647-1671.
84. François A, Laroche A, Pinaud N, et al. Encapsulation of docetaxel into PEGylated gold nanoparticles for vectorization to cancer cells. Chem Med Chem. 2011;6(11):2003-2008.
85. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3): 136-151.
86. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Part 1):6387-6392.
87. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Delivery Rev. 2011;63(3):131-135.
88. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135-146.
89. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov. 2006;5(2):147-159.
90. Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 2009;11(1):195-203.
91. Liu Y, Li K, Liu B, Feng SS. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials. 2010;31(35): 9145-9155.
92. Pangburn TO, Petersen MA, Waybrant B, Adil MM, Kokkoli E. Peptide-and aptamer-functionalized nanovectors for targeted delivery of therapeutics. J Biomech Eng. 2009;131(7):074005.
93. Wang X, WangY, Chen X, Wang J, Zhang X, Zhang Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release. 2009;139(1):56-62.
94. Zhang Y, Wang X, Wang J, Zhang X, Zhang Q. Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharmaceut Res. 2011;28(5):1167-1178.
95. Xie Z, Hu X, Chen X, Lu T, Liu S, Jing X. A biodegradable diblcok copolymer poly (ethylene glycol)-block-poly (L-lactide-co-2-methyl2-carboxyl-propylene carbonate): docetaxel and RGD conjugation. J Appl Polym Sci. 2008;110(5):2961-2970.
96. Naik S, Patel D, Chuttani K, Mishra AK, Misra A. In vitro mechanistic study of cell death and in vivo performance evaluation of RGD grafted PEGylated docetaxel liposomes in breast cancer. Nanomedicine. 2012;8(6):951-962.
97. Ray A, Larson N, Pike DB, et al. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer- RGDfK conjugates. Mol Pharm. 2011;8(4):1090-1099.
98. LuY, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54(5):675-693.
99. Zhang Z, Jia J, Lai Y, Ma Y, Weng J, Sun L. Conjugating folic acid to gold nanoparticles through glutathione for targeting and detecting cancer cells. Bioorgan Med Chem. 2010;18(15):5528-5534.
100. Zhang Y, Chen T. Targeting nanomaterials: future drugs for cancer chemotherapy. Int J Nanomedicine. 2012;7:5283-5286.
101. ZhangY, Hong H, Cai W. Tumor-targeted drug delivery with Aptamers. Curr Med Chem. 2011;18(27):4185-4194.
102. Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides. 2011;21(1):1-10.
103. Dausse E, Da Rocha Gomes S, Toulmé JJ. Aptamers: a new class of oligonucleotides in the drug discovery pipeline? Curr Opin Pharmacol. 2009;9(5):602-607.
104. Dua P, Kim S, Lee D. Nucleic acid aptamers targeting cell-surface proteins. Methods. 2011;54(2):215-225.
105. Missailidis S, Hardy A. Aptamers as inhibitors of target proteins. Expert Opin Ther Pat. 2009;19(8):1073-1082.
106. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-876.
107. Gao L, Cui Y, He Q, Yang Y, Fei J, Li J. Selective recognition of co-assembled thrombin aptamer and docetaxel on mesoporous silica nanoparticles against tumor cell proliferation. Chem-Eur J. 2011;17(47):13170-13174.
108. Gao H, Qian J,Yang Z, et al. Whole-cell SELEX aptamer-functionalised poly (ethyleneglycol)-poly (ε-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials. 2012;33: 6264-6272.
109. Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291-317.
110. Zhai G, Wu J, Yu B, Guo C, Yang X, Lee RJ. A transferrin receptortargeted liposomal formulation for docetaxel. J Nanosci Nanotechnol. 2010;10(8):5129-5136.
111. Gan CW, Feng SS. Transferrin-conjugated nanoparticles of poly (lactide)-d-α-Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials. 2010;31(30):7748-7757.
112. Choi KY, Chung H, Min KH, et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials. 2010;31(1): 106-114.
113. Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Controlled Release. 2010;141(1):2-12.
114. Li X, Tian X, Zhang J, et al. In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel. Int J Nanomedicine. 2011;6:1167-1184.
115. Li S-D, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496-504.
116. Yu D-H, Ban F-Q, Zhao M, et al. The use of nanoparticulate delivery systems in metronomic chemotherapy. Biomaterials. 2013;34(16): 3925-3937.
117. Ernsting MJ, Foltz WD, Undzys E, Tagami T, Li S-D. Tumor-targeted drug delivery using MR-contrasted docetaxel-carboxymethylcellulose nanoparticles. Biomaterials. 2012;33(15):3931-3941.
118. Jäger E, Jäger A, Chytil P, et al. Combination chemotherapy using core-shell nanoparticles through the self-assembly of HPMA-based copolymers and degradable polyester. J Control Release. 2013;165(2): 153-161.
119. Oh KS, Lee H, Kim JY, et al. The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy. J Control Release. 2013;165(1):9-15.
120. Liu Q, Li R, Zhu Z, et al. Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm. 2012;430(1-2):350-358.
121. Ernsting MJ, Murakami M, Undzys E, Aman A, Press B, Li S-D. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release. 2012;162(3): 575-581.
122. Raju A, Muthu MS, Feng S-S. Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv. 2013;10(6):747-760.
123. Gao W, Xiang B, Meng T-T, Liu F, Qi X-R. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides. Biomaterials. 2013;34(16):4137-4139.
124. Zhao J, Mi Y, Feng S-S. Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials. 2013;34(13):3411-3421.
125. Ho KS, Aman AM, Al-awar RS, Shoichet MS. Amphiphilic micelles of poly(2-methyl-2-carboxytrimethylene carbonate-co-D,L-lactide)graft-poly(ethylene glycol) for anti-cancer drug delivery to solid tumours. Biomaterials. 2012;33(7):2223-2229.
126. Chen L, Sha X, Jiang X, Chen Y, Ren Q, Fang X. Pluronic P105/ F127 mixed micelles for the delivery of docetaxel against taxolresistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. Int J Nanomedicine. 2013;8:73-84.
127. Shi J, Zhang H, Wang L, et al. PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor. Biomaterials. 2013;34(1):251-261.
128. Qi C, Zhu YJ, Zhao XY, et al. Highly stable amorphous calcium phosphate porous nanospheres: microwave-assisted rapid synthesis using ATP as phosphorus source and stabilizer, and their application in anticancer drug delivery. Chem-Eur J. 2013;19(3):981-987.
129. Lozano M, Lollo G, Alonso-Nocelo M, et al. Polyarginine nanocapsules: a new platform for intracellular drug delivery. J Nanopart Res. 2013;15:1515.
130. Sun YJ, Dong WB, Wang HY, et al. Template synthesis of PMAA@chitosan hollow nanorods for docetaxel delivery. Polym Chem. 2013;4(8):2489-2495.
131. Arora S, Saharan R, Kaur H, Kaur I, Bubber P, Bharadwaj LM. Attachment of docetaxel to multiwalled carbon nanotubes for drug Delivery applications. Adv Sci Lett. 2012;17(1):70-75.
132. Quan Q, Kim D-W, Marasini N, et al. Physicochemical characterization and in vivo evaluation of solid self-nanoemulsifying drug delivery system for oral administration of docetaxel. J Microencapsul. 2013;30(4):307-314.
133. Li L, Zhang Y, Hao N, Chen D, Tang F. Fabrication of PLGA coated silica nanorattle for controlling the drug release behavior. Chin Sci Bull. 2012;57(27):3631-3638.
134. Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523-580.
135. Ma X, Zhao Y, Liang X-J. Theranostic nanoparticles engineered for clinic and pharmaceutics. Acc Chem Res. 2011;44(10):1114-1122.